醫院傳染病檢查市場 - 全球產業規模、佔有率、趨勢、機會、預測：按檢測類型、感染類型、產品、類型、地區和競爭對手分類，2021-2031年

全球醫院感染檢測市場預計將從 2025 年的 52.9 億美元大幅成長至 2031 年的 83.4 億美元，複合年成長率為 7.88%。

該市場涵蓋一系列篩檢程序和診斷測試，用於檢測醫療機構內傳播給患者的病毒和細菌等傳染性病原體。推動這一市場成長的關鍵因素包括：醫院感染發生率不斷上升、老年人口不斷成長（老年人極易感染此類疾病）、政府加強感染控制措施以及合理使用抗菌藥物方案的必要實施。

儘管有這些成長要素，但市場仍面臨一個重大障礙：先進分子診斷的高成本限制了其在資源匱乏地區的普及。然而，鑑於抗生素抗藥性病原體帶來的嚴重負擔，對這些檢測解決方案的需求仍然強勁。世界衛生組織（世衛組織）的數據凸顯了這種迫切性，預計到2024年，全球將出現約1.36億例抗生素抗藥性醫療相關感染疾病病例，凸顯了有效診斷干預措施的迫切需求。

市場促進因素

快速診斷技術的進步正在從根本上改變全球醫院感染檢測市場，使病原體檢測更加早期和精確。從傳統的培養方法轉向先進的分子診斷技術，特別是症候群檢測，使得醫療專業人員能夠在數小時內而非數天內識別多種感染性病原體。這對於快速啟動抗生素治療和改善患者預後至關重要。這些創新技術的商業性可行性在其日益普及的應用中得到了充分體現。例如，生物梅里埃公司在其2024年9月發布的「2024會計年度上半年財務業績報告」中指出，其用於診斷腦膜炎和敗血症等疾病的BIOFIRE非呼吸道病原體檢測組合的有機銷售額成長了19%。

同時，隨著多重抗藥性病原體的威脅日益加劇，醫療機構爭相對抗超級細菌，對這類先進檢測解決方案的需求也日益成長。隨著抗藥性機制的演變和標準抗生素療效的下降，精準診斷對於制定合理使用抗菌藥物的指南和預防感染傳播至關重要。長期預測也凸顯了這種迫切性。惠康基金會2024年9月的報告預測，2025年至2050年間，將有超過3,900萬人死於抗藥性細菌感染疾病。 2024年7月，美國疾病管制與預防中心（CDC）宣布，多重抗藥性真菌耳Auris的臨床病例自2019年以來增加了約五倍。

市場挑戰

先進分子診斷的高昂成本是限制全球醫院感染檢測市場成長的主要障礙。醫療機構，尤其是資源有限的機構，在權衡採用最先進的篩檢工具與必要的營運成本時，往往面臨艱難的抉擇。因此，準確但昂貴的分子檢測往往難以普及，許多醫療機構被迫依賴傳統的、成本較低的診斷方法，這可能導致必要的治療和感染控制通訊協定的延遲。

這種財政限制也體現在診斷技術投資佔整體醫療保健支出比例相對較低。如果檢測預算撥款與其他醫療保健領域相比仍然過低，市場擴張將受到阻礙。根據歐洲醫療技術協會（MedTech Europe）預測，到2024年，體外診斷支出預計僅佔醫療保健總支出的0.6%。這項數據凸顯了嚴重的預算限制，阻礙了先進檢測解決方案的普及，也使市場無法充分滿足感染疾病帶來的需求。

市場趨勢

即時檢測（POC​​）的普及使得醫院感染的檢測分散化，醫護人員無需等待中心檢查室的檢測結果，即可在患者床邊直接識別病原體。這一轉變顯著縮短了檢測結果的返回時間，從而能夠在疫情爆發時即時做出隔離和治療決策，這對於防止感染擴散至關重要，尤其是在高風險病房。這一趨勢對市場的影響體現在分散式分子平台的快速商業性應用上。例如，2025年3月，生物梅里埃公司報告稱，其SPOTFIRE照護現場解決方案的年銷售額已達到9,500萬歐元，這主要得益於醫療機構中不斷擴大的應用群體。

同時，即時數位監測系統正顯著普及，用於監測整個醫療網路中的感染率和抗生素抗藥性模式。這些系統整合了住院和手術數據，識別高風險區域，並確保符合感染控制標準，從而為管理人員提供持續的回饋機制。參與這些監測計畫推動了對定期檢測的需求，英國衛生安全局2025年12月的報告顯示，提交監測分析的手術數量同比成長7.9%，這反映出醫療機構對監測義務的遵守程度有所提高。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球醫院傳染病檢查市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依檢測類型（分子檢測、常規檢測）
  • 按類型分類的感染疾病（尿道感染、肺炎、手術部位感染、血流感染疾病、其他）
  • 依產品分類（耗材、設備）
  • 依類型（血液檢查、尿液檢查）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美醫療保健傳染病檢查市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲醫院傳染病檢查市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區醫院傳染病檢查市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲醫院傳染病檢查市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲醫院傳染病檢查市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球醫院傳染病檢查市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• bioMerieux SA
• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company
• Bioscience, Inc.
• QIAGEN NV
• Thermo Fisher Scientific Inc
• Hologic, Inc.
• Meridian Bioscience, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Hospital Acquired Disease Testing Market is projected to experience significant growth, expanding from USD 5.29 Billion in 2025 to USD 8.34 Billion by 2031, reflecting a CAGR of 7.88%. This market encompasses various screening procedures and diagnostic assays intended to detect infectious agents, including viruses and bacteria, that are transmitted to patients within medical environments. Key drivers accelerating this growth include the increasing incidence of nosocomial infections and a growing geriatric demographic that is highly vulnerable to such conditions, alongside strict government mandates for infection control and the essential adoption of antimicrobial stewardship programs.

Despite these growth factors, the market faces a substantial obstacle in the form of high costs linked to advanced molecular diagnostics, which restricts their deployment in regions with limited resources. Nevertheless, the demand for these testing solutions remains acute given the heavy burden of resistant pathogens. Data from the World Health Organization underscores this urgency, estimating that in 2024, approximately 136 million antibiotic-resistant healthcare-associated infections occurred globally, highlighting the critical need for effective diagnostic interventions.

Market Driver

Advancements in rapid diagnostic technologies are fundamentally transforming the Global Hospital Acquired Disease Testing Market by facilitating earlier and more precise pathogen detection. The shift from conventional culture-based techniques to sophisticated molecular diagnostics, particularly syndromic testing, enables medical professionals to identify multiple infectious agents in hours instead of days, which is crucial for timely antimicrobial therapy and improved patient outcomes. The commercial viability of these innovations is evident in their increasing adoption; for example, bioMerieux reported in their 'First-Half 2024 Financial Results' in September 2024 that organic sales of their BIOFIRE non-respiratory panels, essential for diagnosing conditions like meningitis and sepsis, rose by 19%.

At the same time, the escalating threat of multidrug-resistant pathogens is driving the necessity for these advanced testing solutions as healthcare facilities fight to control superbugs. As resistance mechanisms evolve and standard antibiotics become less effective, precise diagnostics are essential for guiding antimicrobial stewardship and preventing outbreaks. This urgency is emphasized by long-term forecasts; a September 2024 report by Wellcome predicts over 39 million deaths will be attributed to antibiotic-resistant infections between 2025 and 2050, while the Centers for Disease Control and Prevention noted in July 2024 that reported clinical cases of the multidrug-resistant fungus Candida auris increased nearly five-fold since 2019.

Market Challenge

The substantial expense associated with advanced molecular diagnostics poses a significant barrier to the growth of the Global Hospital Acquired Disease Testing Market. Healthcare institutions, particularly those in resource-limited settings, often face difficult decisions when balancing the acquisition of cutting-edge screening tools against essential operational costs. Consequently, the adoption of precise yet costly molecular assays is often limited, compelling many providers to depend on traditional, less expensive diagnostic methods that may delay necessary treatment and infection control protocols.

This financial constraint is further illustrated by the relatively low investment in diagnostic technologies compared to overall healthcare spending. Market expansion is stifled when budgetary allocations for testing remain disproportionately small relative to other medical verticals. According to MedTech Europe, expenditure on in vitro diagnostics in 2024 was estimated to account for only 0.6% of total healthcare spending. This statistic underscores the severe budgetary limitations that hinder the uptake of advanced testing solutions, preventing the market from fully addressing the demand generated by the prevalence of infectious diseases.

Market Trends

The expansion of Point-of-Care (POC) testing is decentralizing the detection of hospital-acquired diseases, enabling healthcare providers to identify pathogens directly at the bedside rather than waiting for central laboratory results. This transition significantly lowers turnaround times, allowing for immediate isolation and treatment decisions that are vital for containing outbreaks in sensitive wards. The market impact of this trend is highlighted by the swift commercial adoption of decentralized molecular platforms; for instance, bioMerieux reported in March 2025 that sales of its SPOTFIRE point-of-care solution reached €95 million for the year, driven by a growing installed base across medical facilities.

Concurrently, there is a notable shift toward real-time digital surveillance systems designed to monitor infection rates and antimicrobial resistance patterns throughout healthcare networks. These systems compile data from inpatient stays and surgical procedures to pinpoint high-risk areas and ensure compliance with infection control standards, creating a continuous feedback loop for administrators. Participation in these monitoring programs is fueling demand for consistent testing, as evidenced by the UK Health Security Agency's December 2025 report, which noted a 7.9% increase in the volume of surgical procedures submitted for surveillance analysis compared to the previous year, reflecting increased adherence to monitoring mandates.

Key Market Players

• bioMerieux SA
• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company
• Bioscience, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc
• Hologic, Inc.
• Meridian Bioscience, Inc

Report Scope

In this report, the Global Hospital Acquired Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hospital Acquired Disease Testing Market, By Test Type

• Molecular
• Conventional

Hospital Acquired Disease Testing Market, By Infection Type

• UTI
• Pneumonia
• Surgical Site Infection
• Blood Stream Infections
• Others

Hospital Acquired Disease Testing Market, By Product

• Consumables
• Instruments

Hospital Acquired Disease Testing Market, By Type

• Blood Tests
• Urinalysis

Hospital Acquired Disease Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hospital Acquired Disease Testing Market.

Available Customizations:

Global Hospital Acquired Disease Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hospital Acquired Disease Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Molecular, Conventional)
  • 5.2.2. By Infection Type (UTI, Pneumonia, Surgical Site Infection, Blood Stream Infections, Others)
  • 5.2.3. By Product (Consumables, Instruments)
  • 5.2.4. By Type (Blood Tests, Urinalysis)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Hospital Acquired Disease Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Infection Type
  • 6.2.3. By Product
  • 6.2.4. By Type
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hospital Acquired Disease Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Infection Type
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Type
  • 6.3.2. Canada Hospital Acquired Disease Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Infection Type
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Type
  • 6.3.3. Mexico Hospital Acquired Disease Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Infection Type
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Type

7. Europe Hospital Acquired Disease Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Infection Type
  • 7.2.3. By Product
  • 7.2.4. By Type
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hospital Acquired Disease Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Infection Type
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Type
  • 7.3.2. France Hospital Acquired Disease Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Infection Type
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Type
  • 7.3.3. United Kingdom Hospital Acquired Disease Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Infection Type
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Type
  • 7.3.4. Italy Hospital Acquired Disease Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Infection Type
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Type
  • 7.3.5. Spain Hospital Acquired Disease Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Infection Type
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Type

8. Asia Pacific Hospital Acquired Disease Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Infection Type
  • 8.2.3. By Product
  • 8.2.4. By Type
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hospital Acquired Disease Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Infection Type
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Type
  • 8.3.2. India Hospital Acquired Disease Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Infection Type
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Type
  • 8.3.3. Japan Hospital Acquired Disease Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Infection Type
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Type
  • 8.3.4. South Korea Hospital Acquired Disease Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Infection Type
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Type
  • 8.3.5. Australia Hospital Acquired Disease Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Infection Type
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Type

9. Middle East & Africa Hospital Acquired Disease Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Infection Type
  • 9.2.3. By Product
  • 9.2.4. By Type
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hospital Acquired Disease Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Infection Type
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Type
  • 9.3.2. UAE Hospital Acquired Disease Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Infection Type
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Type
  • 9.3.3. South Africa Hospital Acquired Disease Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Infection Type
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Type

10. South America Hospital Acquired Disease Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Infection Type
  • 10.2.3. By Product
  • 10.2.4. By Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hospital Acquired Disease Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Infection Type
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Type
  • 10.3.2. Colombia Hospital Acquired Disease Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Infection Type
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Type
  • 10.3.3. Argentina Hospital Acquired Disease Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Infection Type
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hospital Acquired Disease Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. bioMerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Siemens Healthcare Private Limited
• 15.5. Becton, Dickinson and Company
• 15.6. Bioscience, Inc.
• 15.7. QIAGEN N.V.
• 15.8. Thermo Fisher Scientific Inc
• 15.9. Hologic, Inc.
• 15.10. Meridian Bioscience, Inc

16. Strategic Recommendations

17. About Us & Disclaimer